Christopher T. Griffith

Christopher T. Griffith

Attorney Profile

Top Rated Intellectual Property Litigation Attorney in Chicago, IL

Green, Griffith & Borg-Breen LLP
 | 676 N. Michigan Avenue, Suite 3900
Chicago, IL 60611
Phone: 312-883-8008
Fax: 312-883-8001
Selected to Super Lawyers: 2016 - 2019
Licensed Since: 1988
Practice Areas:
  • Intellectual Property Litigation (70%),
  • Intellectual Property (30%)
Attorney Profile

Chris Griffith is a founding partner of Green, Griffith & Borg-Breen LLP.  A seasoned IP trial lawyer with over 30 years of experience in IP law, his practice concentrates on pharmaceuticals, chemicals, medical devices and biotechnology.  He has been lead counsel in trials and appeals, representing both patentees and defendants, before the U.S. District Courts and the Federal Circuit.

A Hatch-Waxman expert, he partners with clients to provide strategic formulation, portfolio and pre-litigation counseling concerning IP and related FDA issues affecting 505(b)(1), 505(b)(2) and ANDA applications, as well as IP issues arising concerning biologics under the BPCIA.

With expertise gained by representing brand and generic companies, he provides strategies and opinions (validity, freedom-to-operate) directed toward attaining client goals, whether this involves API/excipient selection, trade dress, formulation attributes, or labeling, and then works with clients to execute the desired strategy – whether this involves litigation in the federal courts, IPRs or arbitration. 

Chris has been instrumental in obtaining favorable outcomes.  Recently, he was counsel for Horizon in successful Hatch-Waxman litigations concerning PENNSAID® 2% against several ANDA challengers, resulting in settlements with favorable generic entry dates and judgment of infringement/not invalid against Actavis/TEVA.  He also was counsel for Dexcel in a successful declaratory judgment action against Takeda involving Dexcel’s 505(b)(2) OTC lansoprazole product.  Other successful outcomes include the first generic for PLENDIL® and the invalidation of Orange Book patents on GENERESS FE®. 

Chris and his team are also skilled in inter partes reviews (IPRs), as well as in reexaminations, reissues and post-grant proceedings under the AIA.  He has significant experience in navigating the 505(b)(2) pathway, including advising clients on PIV certifications, Orange Book issues, related FDA issues, and portfolio development.  Due diligence is also a strength.    

Chris enjoys lecturing and teaching, and is a former adjunct professor at The John Marshall Law School, where he developed a Master's level course in patent law, and taught that course for many years.

Prior to co-founding Green Griffith in 2015, Chris was Corporate Secretary of Leydig, Voit & Mayer, Ltd. and served on its Board of Directors.

About Christopher Griffith

Admitted: 1988, Illinois

Professional Webpage: http://greengriffith.com/christopher-t-griffith/

Honors/Awards:

  • Selected as a “Life Sciences Star,” LMG Life Sciences
  • Named as a “Global IP Star,” Managing IP
  • Listed in Intellectual Asset Management's (IAM) Patent 1000 in Litigation
  • Selected by peers as a “Leading Lawyer” in Intellectual Property Law – Leading Lawyers Network
  • Recognized by Illinois Super Lawyers in Intellectual Property Litigation
  • Listed among the “Top Lawyers in Illinois” in Intellectual Property Law – Chicago Lawyer

Special Licenses/Certifications:

  • U.S. Court of Appeals for the Federal Circuit; U.S. District Court for the Northern District of Illinois (Member, Trial Bar); U.S. District Court for the District of Arizona; U.S. District Court for the District of Columbia; U.S. District Court for the District of Delaware; U.S. District Court for the Southern District of Florida; U.S. District Court for the Northern District of Georgia;  U.S. District Court for the District of Nevada; U.S. District Court for the District of New Jersey; U.S. District Court for the Southern District of New York; U.S. District Court for the Northern District of Ohio; U.S. District Court for the Eastern District of Pennsylvania; U.S. District Court for the Western District of Washington; Registered Patent Attorney, U.S. Patent and Trademark Office, No. 33,392 (list includes pro hac vice admissions)

Bar/Professional Activity:

  • Adjunct Professor, John Marshall Law School, Chicago, IL (Masters Level Course in Patent Law), 2002-2016

Pro bono/Community Service:

  • Pro bono representation of prisoner in federal court seeking remedy for alleged improper healthcare.

Scholarly Lectures/Writings:

  • “IP in the Courts: The Latest in IP Litigation,” World Intellectual Property Forum 2018 (WIPF), New Delhi, India, November 2018; “Navigating the IP/FDA Exclusivity Waters – Recent Developments Affecting the Journey to 505(b)(1), 505(b)(2), ANDA and Biologics Approval in the US,” 3rd Annual China Pharma IP Summit, Beijing, China, October 2018;  "Paragraph IV Litigation Trends, Analysis and Future Predictions" and "Strategic Considerations Concerning Inter Partes Reviews (IPRs) - Appearing in Dual Proceedings Before the U.S. District Court and PTAB," 3rd International IP Skills Summit (IIPSS), Hyderabad, India, June 2018;  “Interplay Between FDA Exclusivity, PTAB/IPRs and Hatch-Waxman Litigation on the Filing and Approval of 505(b)(2) and ANDA Applications,” 8th Annual Generic International Summit Asia, Shanghai, China, April 2018; “Latest Developments: Federal Courts and PTAB,” 7th Annual Pharma IPR Conference, Mumbai, India, March, 2018; “505(b)(2) NDAs v. ANDAs: Case Studies and Implications for Patent Portfolio Development and US Litigation,” 2nd China Pharma IP Summit 2017, Shanghai, China, December 2017; “Exploring New Developments in the Law of Divided and Inducement Infringement and Its Continuing Impact on Paragraph IV Litigation,” Paragraph IV Disputes Master Symposium, Chicago, IL, October 2017; “Selected U.S. Patent Law Topics Relevant to Pharmaceutical and Biotech Practice (Patentability, Validity and Infringement),” Advanced Training Seminars for the All-China Patent Agents Association, Chicago, IL, September 2014, July and November 2013; "Current Issues and Strategies in U.S. Patent Prosecution,” Advanced Training Seminar for Patent Reexaminers of the People’s Republic of China (SIPO), Chicago, IL, June and October 2013; “Selected U.S. Patent Law Topics Relevant to Pharmaceutical and Biotech Practice (Patentability, Validity and Infringement),” Advanced Training Seminars for the All-China Patent Agents Association and State Intellectual Property Organization (SIPO), Chicago, IL, May, September and October 2012; “Patent Litigation Issues in the Context of Biotechnology and Pharmaceutical Patents,” Advanced Training Seminar for the All-China Patent Agents Association, Chicago, IL, June and September 2011; U.S. Patent Law and Pharmaceuticals--Current and Future Trends, February, 2008 (Mumbai, India); October 2007: Current Issues and Strategies in U.S. Patent Prosecution: Advanced Training Seminar for Patent Reexaminers of the People's Republic of China (Chicago, Illinois); February 2007:  Recent Developments in U.S. Patent Law Affecting the Pharmaceutical Industry, Global Generic Pharmaceutical Conference 2007 (Mumbai, India); December 2006: Patent Considerations in the Pharmaceutical Industry, 58th Indian Pharmaceutical Congress (Mumbai, India); October 2006: Current Issues and Strategies in U.S. Patent Prosecution: Advanced Training Seminar for Patent Reexaminers of the People's Republic of China (Chicago, Illinois); June 2006:  Patent Barriers to Generic Pharmaceutical Entry, AIPLA Road Shows (Boston, Houston, San Jose); March 2006: The Changing Landscape of U.S. Patent Law, Global Generic Pharmaceutical Conference 2006 (Mumbai, India); October 2005:  Patent Issues and Trends In Cosmetic Formulations, Society of Cosmetic Chemists (Chicago); March 2003 & 2004:  Due Diligence in IP Business Transactions, Practicing Law Institute (Chicago) September, 2002; "Senate Passes Bill Revising Hatch-Waxman Framework for Generic Drug Approval," Regulatory Affairs FOCUS (Regulatory Affairs Professionals Society) March 2001;  Presentation on Process Patents, National Association of Pharmaceutical and Manufacturers Bulk Drug Workshop (New York City) January 2000;  Presentation on Process Patents and Related Issues, National Association of Pharmaceutical Manufacturers Annual Meeting (San Juan, Puerto Rico) 1999; Presentations on patent law (patentability/freedom-to-operate/opinions) to client R&D teams

Educational Background:

  • B.S., Chemical and Biomedical Engineering, Michigan State University
  • JD, University of Houston
  • Masters Level Coursework in Biotechnology, Johns Hopkins University

Industry Groups

  • Pharma; BioPharma; Biologics; Chemicals; Medical Devices
Office Location for Christopher T. Griffith

676 N. Michigan Avenue
Suite 3900
Chicago, IL 60611

Christopher T. Griffith:

Last Updated: 9/10/2018

Page Generated: 0.27130198478699 sec